Analyst Ratings For NASDAQ:OBLN – Obalon Therapeutics (NASDAQ:OBLN)
Today, NASDAQ:OBLN – Obalon Therapeutics (NASDAQ:OBLN) stock was downgraded by Northland Securities from Market Perform ➝ Underperform to .
Some recent analyst ratings include
- 5/11/2018-Northland Securities was Downgraded by analysts at Northland Securities from a “Market Perform ➝ Underperform” rating to a “” rating.
- 3/6/2018-Stifel Nicolaus Reiterated Rating of Buy.
- 3/6/2018-Canaccord Genuity Reiterated Rating of Buy ➝ Buy.
Recent Insider Trading Activity For NASDAQ:OBLN – Obalon Therapeutics (NASDAQ:OBLN)
NASDAQ:OBLN – Obalon Therapeutics (NASDAQ:OBLN) has insider ownership of 16.40% and institutional ownership of 42.42%.
- On 3/15/2018 Neil Drake, VP, bought 5,000 with an average share price of $3.96 per share and the total transaction amounting to $19,800.00.
- On 3/14/2018 William J Plovanic, CFO, bought 30,000 with an average share price of $4.04 per share and the total transaction amounting to $121,200.00.
- On 10/12/2016 Kim P Kamdar, Director, bought 13,400 with an average share price of $15.00 per share and the total transaction amounting to $201,000.00.
- On 10/12/2016 Matthew Norwood, VP, bought 1,000 with an average share price of $15.00 per share and the total transaction amounting to $15,000.00.
Recent Trading Activity for NASDAQ:OBLN – Obalon Therapeutics (NASDAQ:OBLN)
Shares of NASDAQ:OBLN – Obalon Therapeutics closed the previous trading session at with 3.7899999618530273 shares trading hands.
